264 related articles for article (PubMed ID: 31120565)
1. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
Liu Y; West R; Weber JD; Colditz GA
Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
[TBL] [Abstract][Full Text] [Related]
2. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ.
Dania V; Liu Y; Ademuyiwa F; Weber JD; Colditz GA
Breast Cancer Res; 2019 Nov; 21(1):120. PubMed ID: 31727116
[TBL] [Abstract][Full Text] [Related]
3. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
[TBL] [Abstract][Full Text] [Related]
4. Racial disparities in risk of second breast tumors after ductal carcinoma in situ.
Liu Y; Colditz GA; Gehlert S; Goodman M
Breast Cancer Res Treat; 2014 Nov; 148(1):163-73. PubMed ID: 25261293
[TBL] [Abstract][Full Text] [Related]
5. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
[TBL] [Abstract][Full Text] [Related]
6. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype.
Hausauer AK; Keegan TH; Chang ET; Clarke CA
Breast Cancer Res; 2007; 9(6):R90. PubMed ID: 18162138
[TBL] [Abstract][Full Text] [Related]
7. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
8. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
9. Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer.
Giannakeas V; Sopik V; Narod SA
JAMA Netw Open; 2020 Sep; 3(9):e2017124. PubMed ID: 32936299
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P
JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women.
Bertrand KA; Bethea TN; Rosenberg L; Bandera EV; Khoury T; Troester MA; Ambrosone CB; Palmer JR
Breast; 2020 Feb; 49():108-114. PubMed ID: 31786415
[TBL] [Abstract][Full Text] [Related]
12. Recent trends in breast cancer among younger women in the United States.
Brinton LA; Sherman ME; Carreon JD; Anderson WF
J Natl Cancer Inst; 2008 Nov; 100(22):1643-8. PubMed ID: 19001605
[TBL] [Abstract][Full Text] [Related]
13. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
14. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA
JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328
[TBL] [Abstract][Full Text] [Related]
15. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women?
Warner ET; Tamimi RM; Boggs DA; Rosner B; Rosenberg L; Colditz GA; Palmer JR
Cancer Causes Control; 2013 Apr; 24(4):731-9. PubMed ID: 23380944
[TBL] [Abstract][Full Text] [Related]
17. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
[TBL] [Abstract][Full Text] [Related]
18. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
[TBL] [Abstract][Full Text] [Related]
19. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
Elledge RM; Clark GM; Chamness GC; Osborne CK
J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
[TBL] [Abstract][Full Text] [Related]
20. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
